Actively Recruiting

Age: 18Years +
All Genders
NCT04608357

Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients

Led by Sunnybrook Health Sciences Centre · Updated on 2025-01-20

25

Participants Needed

1

Research Sites

332 weeks

Total Duration

On this page

Sponsors

S

Sunnybrook Health Sciences Centre

Lead Sponsor

A

AFP Innovation Fund

Collaborating Sponsor

AI-Summary

What this Trial Is About

The investigators propose to use clinically validated patient avatar technology ("PDXovo") that can test multiple drugs against patients' cancers to identify the most promising systemic therapy for each individual.

CONDITIONS

Official Title

Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18+ years
  • Diagnosis of metastatic breast cancer regardless of subtype
  • Measurable disease based on RECIST 1.1 criteria
  • Metastatic disease involving lymph nodes and/or visceral organs
  • Willing to undergo biopsy before starting planned systemic therapy
Not Eligible

You will not qualify if you...

  • Core biopsy of a metastatic site (other than bone) is not feasible or safe
  • Unable to provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada, M4N 3M5

Actively Recruiting

Loading map...

Research Team

K

Katarzyna J Jerzak, MD MSc FRCPC

CONTACT

H

Hon S Leong

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here